Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • larshansson18 larshansson18 Jun 18, 2009 1:53 PM Flag

    back to 66 cents

    I liked that one.

    So we are both in it for a better deal than 15% and 10 million as upfront? It's just so hard waiting?

    The IDIS agreement must be painful for you.

    Or - Do you acctually admit that if a sellforce of Epicept sells 3000 Ceplene treatments in Europe the BP could never - never - sell for a higher net revenue than Epicept taking the gross them selfs, given the limitation of the new patient group each year (16 000)? Using your figures (15%) as assumtions.

    How will your next post about the dilution gost look like?

    I'll give you a clue: You have to show that the IDIS agreement given a life safing drug with exclusive rights on the market will not reach the market. My figures of at least 100 new treatments each month is all wrong.

    I hope this discussion might be seen as a metaphor for the negotiations and where the energy is right now.

    In broken English,
    M.

 
IMNP
1.33+0.12(+9.92%)Aug 27 3:59 PMEDT